[HTML][HTML] Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells
S Rocco, A Maglione, V Schiavo, A Ferrando… - Journal of Clinical …, 2025 - mdpi.com
Background/Objectives: Treatment with tyrosine kinase inhibitors (TKIs) in chronic myeloid
leukemia (CML) has revolutionized disease management and has transformed CML from a …
leukemia (CML) has revolutionized disease management and has transformed CML from a …
Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia
AZ Karabay, T Ozkan, A Karadag Gurel, A Koc… - Naunyn-Schmiedeberg's …, 2024 - Springer
Chemotherapy resistance is a major obstacle in cancer therapy, and identifying novel
druggable targets to reverse this phenomenon is essential. The exosome-mediated …
druggable targets to reverse this phenomenon is essential. The exosome-mediated …
Global DNA Methylation analysis of imatinib resistant and sensitive K562 cells
Y Hekmatshoar - Ege Tıp Bilimleri Dergisi, 2024 - dergipark.org.tr
OBJECTIVE: Chronic myeloid leukemia (CML) is a hematological disease which is known
by the presence of Philadelphia chromosome (Ph+). BCR-ABL protein is expressed by Ph+ …
by the presence of Philadelphia chromosome (Ph+). BCR-ABL protein is expressed by Ph+ …